Huami Launches Medical Expert Team to Advance Cardiovascular Lifecycle Health Management

As a global leader in smart wearables, Huami Technology (NYSE: HMI) has been committed to leveraging the power of technology to provide better sports, health, and medical services for everyone. Recently, its Medical Services and Research Team was officially unveiled. This team will work in conjunction with smart wearable devices to create a closed-loop cardiovascular health service system, helping users achieve the most convenient full-cycle health management.

It is understood that the team comprises subgroups dedicated to medical technology support, clinical trials, and medical product registration, and currently consists of more than ten full-time medical technical professionals. Among them, 90% hold master’s or doctoral degrees. The team includes two senior-title professionals: one Chief Physician, one Associate Researcher, and six Attending Physicians. The team will be responsible for the research and development and technical support of wearable medical health products, assist in the analysis and processing of online and offline health data, and provide users with professional and timely health management and consultation services.

Cardiovascular disease is one of the most common major diseases in China. According to the Report on Cardiovascular Diseases in China 2018, there are approximately 290 million patients with cardiovascular diseases nationwide. Deaths from cardiovascular diseases account for more than 40% of all disease-related deaths among Chinese residents, posing a significant threat to life and health. Therefore, early prevention and detection are crucial. By leveraging the ECG monitoring capabilities of wearable devices to provide users with professional electrocardiogram interpretation and related services, Huami Technology has been deeply committed to this area as part of its long-term strategy in healthcare.

In this regard, Huami Technology’s medical team currently comprises five cardiologists and one attending physician of traditional Chinese medicine specializing in chronic disease management. Prior to joining Huami Technology, these professionals served as clinicians at top-tier (Grade 3A) hospitals in Beijing, such as the Chinese PLA General Hospital, Beijing Friendship Hospital, and Peking University People’s Hospital, or as researchers at academic institutions like Tsinghua University. They possess extensive clinical experience, comprehensive health management expertise, and strong research capabilities.

Dr. Ding Zhongru, the team leader, previously served as Deputy Director of the Cardiovascular Center at the Eighth Medical Center of the Chinese PLA General Hospital prior to joining. He has held positions including Committee Member of the Cardiology Professional Committee of the Jiangxi Branch of the Chinese Medical Association, Standing Committee Member of the Jiangxi Society for Cardiac Pacing and Electrophysiology, and Standing Committee Member of the Integrated Traditional Chinese and Western Medicine Cardiology Branch of the Chinese Medical Association.

Over the past three decades, Dr. Ding has been primarily engaged in clinical and basic research on coronary heart disease, arrhythmias, congenital heart disease, and cardiovascular genetic disorders. He specializes in the management of critical cases in cardiology, as well as interventional diagnosis and treatment for coronary heart disease, congenital heart disease, and arrhythmias. He served as the principal investigator for a key funded project of the Nanjing Military Region, received two Third-Prize Awards for Military Scientific and Technological Progress, and published more than 70 papers in domestic core journals, statistical source journals, and SCI-indexed journals. Additionally, he contributed to the authorship of eight monographs on cardiology.

Liu Yanzhen, an Associate Research Fellow responsible for medical product registration and medical device quality management at Huami Technology, previously worked at the National Institutes for Food and Drug Control (NIFDC) for over a decade, specializing in the testing of active medical devices. She participated in the testing and evaluation of multiple national innovative medical devices and consecutively led and took part in national medical device supervisory sampling programs for many years. Furthermore, she has been involved in several national 863 Program projects, National Key R&D Programs, as well as research projects under the 12th and 13th Five-Year Plans. She also led the development of one industry standard for medical devices and contributed to the formulation of three others.

Huami Technology was founded in 2013 and quickly initiated its strategic layout in the healthcare sector. In December 2016, Anhui Huami Health Medical Co., Ltd. was officially established. In April 2017, the company officially launched its proprietary brand, the AMAZFIT Mi Band Health Edition, creatively introducing ECG (electrocardiogram) functionality into smart wearable devices. By integrating various health metrics, it provides users with more scientific and effective health management models and services. In September 2018, following comprehensive upgrades to both ECG monitoring and PPG (photoplethysmography) heart rate monitoring, the company released the Mi Band Health Edition 1S, which leverages AI algorithms to provide 24/7 real-time monitoring for cardiac issues.

In January 2018, the wearable dynamic ECG recorder developed by Huami Technology received CFDA certification, marking a significant breakthrough in healthcare.

In March 2019, Huami (Beijing) Medical Health Technology Co., Ltd. was officially established. On June 11 this year, Huami Technology launched the AMAZFIT Mi Move Health Watch, pioneering a new category of smartwatches focused on health. The device is equipped with “Huangshan No. 1,” the world’s first artificial intelligence chip designed for smart wearables. Leveraging an ECG heart rate sensor and an AI-driven biological data engine, it enables over-the-counter electrocardiogram (ECG) measurements and 24/7 arrhythmia monitoring. Following its official market release, the watch integrates with the new Mi Move Health VIP service to provide users with enhanced health and medical consultation recommendations, thereby offering better management tools to mitigate cardiac health risks.

As of March 31, 2019, the cumulative global shipments of Huami Technology’s smart wearable devices reached 84.9 million units. Data from Mi Move Big Data shows that these devices have recorded a cumulative total of 64.7 trillion steps, 6.1 billion nights of sleep, and 13.7 billion hours of heart rate monitoring, while ECG (electrocardiogram) data has accumulated to 12.73 million records. Leveraging Mi Move Big Data, Huami Technology has successively released the Sports White Paper, the Sleep White Paper, and the Heart Health White Paper, featuring sample sizes in the tens of millions—a scale unprecedented in history.